Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Deferred Taxes (2016 - 2018)

Spero Therapeutics' Deferred Taxes history spans 3 years, with the latest figure at $645000.0 for Q4 2018.

  • For Q4 2018, Deferred Taxes rose 2054.55% year-over-year to $645000.0; the TTM value through Dec 2018 reached $554000.0, up 532.81%, while the annual FY2018 figure was $554000.0, 532.81% up from the prior year.
  • Deferred Taxes reached $645000.0 in Q4 2018 per SPRO's latest filing, up from -$32000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $645000.0 in Q4 2018 to a low of -$497000.0 in Q1 2017.
  • Average Deferred Taxes over 3 years is $44222.2, with a median of -$32000.0 recorded in 2018.
  • The largest YoY upside for Deferred Taxes was 2054.55% in 2018 against a maximum downside of 105.29% in 2018.
  • A 3-year view of Deferred Taxes shows it stood at -$28000.0 in 2016, then fell by 17.86% to -$33000.0 in 2017, then soared by 2054.55% to $645000.0 in 2018.
  • Per Business Quant, the three most recent readings for SPRO's Deferred Taxes are $645000.0 (Q4 2018), -$32000.0 (Q3 2018), and -$23000.0 (Q2 2018).